In fact, a limiting factor in our study was the lack of laboratory data, including IgE levels and eosinophils counts, which may allow us to glean insights into which patients may be at risk for AA in the setting of dupilumab for AD. This evidence concerns the gene IGHE and Alzheimer disease.